A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019.
作者信息
Zhang Fengqin, Wei Yanqiu, He Li, Zhang Huilan, Hu Qiongjie, Yue Huihui, He Jianhan, Dai Huaping
机构信息
Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 10029, China.
出版信息
Chin Med J (Engl). 2021 Dec 1;135(3):368-370. doi: 10.1097/CM9.0000000000001614.
Abstract
摘要
相似文献
1
A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019.
Chin Med J (Engl). 2021 Dec 1;135(3):368-370. doi: 10.1097/CM9.0000000000001614.
2
Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.
Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228-9; author reply 1229. doi: 10.1164/ajrccm.172.9.951.
3
Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
Pharmacol Rep. 2021 Jun;73(3):712-727. doi: 10.1007/s43440-021-00255-x. Epub 2021 Apr 21.
4
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23.
5
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761. doi: 10.1164/rccm.201701-0091OC.
6
The questionable efficacy of pirfenidone in IPF.
Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228. doi: 10.1164/ajrccm.172.9.950.
7
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Expert Rev Respir Med. 2014 Oct;8(5):539-45. doi: 10.1586/17476348.2014.915750. Epub 2014 Aug 12.
8
A pilot study in patients with established advanced liver fibrosis using pirfenidone.
Gut. 2006 Nov;55(11):1663-5. doi: 10.1136/gut.2006.107136.
9
Pirfenidone: in idiopathic pulmonary fibrosis.
Drugs. 2011 Sep 10;71(13):1721-32. doi: 10.2165/11207710-000000000-00000.
10
Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Pulm Pharmacol Ther. 2017 Oct;46:48-53. doi: 10.1016/j.pupt.2017.08.011. Epub 2017 Aug 24.
引用本文的文献
1
Dual threat: Susceptibility mechanisms and treatment strategies for COVID-19 and bacterial co-infections.
Comput Struct Biotechnol J. 2025 May 22;27:2107-2122. doi: 10.1016/j.csbj.2025.05.033. eCollection 2025.
2
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.
Eur Respir J. 2025 Apr 24;65(4). doi: 10.1183/13993003.02249-2024. Print 2025 Apr.
3
Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.
Front Med (Lausanne). 2024 Aug 6;11:1411279. doi: 10.3389/fmed.2024.1411279. eCollection 2024.
4
The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks.
BMC Pulm Med. 2024 Apr 2;24(1):160. doi: 10.1186/s12890-024-02947-5.
5
Pharmacological approaches to pulmonary fibrosis following COVID-19.
Front Pharmacol. 2023 Jun 15;14:1143158. doi: 10.3389/fphar.2023.1143158. eCollection 2023.
6
Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology.
Front Immunol. 2023 May 12;14:1185233. doi: 10.3389/fimmu.2023.1185233. eCollection 2023.
7
Post-COVID Interstitial Lung Disease and Other Lung Sequelae.
Clin Chest Med. 2023 Jun;44(2):263-277. doi: 10.1016/j.ccm.2022.11.019. Epub 2023 Mar 3.
8
Microvascular significance of TGF-β axis activation in COVID-19.
Front Cardiovasc Med. 2023 Jan 6;9:1054690. doi: 10.3389/fcvm.2022.1054690. eCollection 2022.
9
The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia.
Pharmaceuticals (Basel). 2022 Dec 16;15(12):1574. doi: 10.3390/ph15121574.
10
Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm.
Healthcare (Basel). 2022 Nov 28;10(12):2387. doi: 10.3390/healthcare10122387.
Zotero 插件